Martina Imbimbo (@mimbimbo1) 's Twitter Profile
Martina Imbimbo

@mimbimbo1

ID: 917832275416551425

calendar_today10-10-2017 19:20:41

63 Tweet

139 Followers

197 Following

Pulmonary Cell News (@pulmonary_news) 's Twitter Profile Photo

💫 Between myth and reality! #NSCLC Dr. Martina Imbimbo's (Martina Imbimbo) team at CHUV / Centre hospitalier universitaire vaudois #review the current state and modalities of adoptive #CellTherapy (ACT) in non-small cell lung carcinoma. 🔗 bit.ly/45PVVUh

💫 Between myth and reality! #NSCLC

Dr. Martina Imbimbo's (<a href="/MImbimbo1/">Martina Imbimbo</a>) team at <a href="/CHUVLausanne/">CHUV / Centre hospitalier universitaire vaudois</a> #review the current state and modalities of adoptive #CellTherapy (ACT) in non-small cell lung carcinoma.

🔗 bit.ly/45PVVUh
Martina Imbimbo (@mimbimbo1) 's Twitter Profile Photo

🚨Cellular therapies and lung cancer. Where are we? What's new? Hope or hype? Alex Friedlaender Read our review to find out 👇👇👇👇 rdcu.be/dkOf2

Martina Imbimbo (@mimbimbo1) 's Twitter Profile Photo

Want to be update on the state-of-art for treatment for Lung Cancer, and much more? Join in person or online, terrific faculty! lungcancer-milan.com Giuseppe Lo Russo Congress is in English!

Want to be update on the state-of-art for treatment for Lung Cancer, and much more?
Join in person or online, terrific faculty!
lungcancer-milan.com
<a href="/GLoRussoMD_PhD/">Giuseppe Lo Russo</a>

Congress is in English!
Mario Occhipinti (@mocchipintimd) 's Twitter Profile Photo

Results from RELEVENT trial confirm the role of antiangionetic in TC. The best first plus chemo: ORR 80%, DCR 100%, PFS 18mo and OS 43mo. Good safety profile. 💥💥💥 Istituto Tumori and TYME network #ESMO23

Results from RELEVENT trial confirm the role of antiangionetic in TC. The best first plus chemo: ORR 80%, DCR 100%, PFS 18mo and OS 43mo. Good safety profile. 💥💥💥  <a href="/IstTumori/">Istituto Tumori</a> and TYME network #ESMO23
Martina Imbimbo (@mimbimbo1) 's Twitter Profile Photo

So proud to see the amazing results of this Italian collaborative effort (Tyme network) at ESMO 23. A big step ahead for patients affected by this rare cancer

Martina Imbimbo (@mimbimbo1) 's Twitter Profile Photo

Terrific congress, so honored to be in the faculty and share the session with 2 giants. Thanks to organizers for the comprehensive program, outstanding faculty and focus on translation research #IO23 IASLC Roberto Ferrara

Martina Imbimbo (@mimbimbo1) 's Twitter Profile Photo

Just out ph2 MEDIOLA trial Toward a chemo free regimen for women affected by ovarian cancer? 👇👇 - Olaparib + durva ➡️ notable activity in women with gBRCAm PSROC - Olaparib + durva + beva ➡️ encouraging activity in women with non-gBRCAm PSROC aacrjournals.org/clincancerres/…

Martina Imbimbo (@mimbimbo1) 's Twitter Profile Photo

AI will be more and more a tool for today's and tomorrow's oncologists. Don't miss this opportunity to showcase your work and connect with great faculty! #AIisthenewstethoscope(cit.)

Rita Leporati (@ritalepp) 's Twitter Profile Photo

Don’t miss the V edition of the #CocktailWithScience #LungCancer meeting in Milan🫁 👉🏻 lungcancer-milan.com Hosted by Giuseppe Lo Russo with a world-class faculty

Don’t miss the V edition of the #CocktailWithScience #LungCancer meeting in Milan🫁

👉🏻 lungcancer-milan.com

Hosted by <a href="/GLoRussoMD_PhD/">Giuseppe Lo Russo</a> with a world-class faculty
Martina Imbimbo (@mimbimbo1) 's Twitter Profile Photo

Amazing opportunity Raffaele Califano My time at the Christie has been so important in my development, as a clinician, researcher and person. Supporting mentors and high quality complete training.

Julien Mazieres (@julienmazieres) 's Twitter Profile Photo

Last brilliant and comprehensive talk by ⁦Roberto Ferrara⁩ on resistance to immunotherapy covering multiple strategies to overcome complex mechanisms of resistance. Towards perfect days ?? #ELCC2025. What a session !!! 👏👏👏

Last brilliant and comprehensive talk by ⁦<a href="/RobertoFerrara_/">Roberto Ferrara</a>⁩ on resistance to immunotherapy covering multiple strategies to overcome complex mechanisms of resistance. Towards perfect days ?? #ELCC2025. What a session !!! 👏👏👏